UK markets closed
  • FTSE 100

    7,018.60
    -140.92 (-1.97%)
     
  • FTSE 250

    17,972.69
    -359.00 (-1.96%)
     
  • AIM

    833.59
    -13.83 (-1.63%)
     
  • GBP/EUR

    1.1189
    -0.0251 (-2.19%)
     
  • GBP/USD

    1.0857
    -0.0398 (-3.54%)
     
  • BTC-GBP

    17,409.57
    -473.89 (-2.65%)
     
  • CMC Crypto 200

    434.61
    -9.92 (-2.23%)
     
  • S&P 500

    3,693.23
    -64.76 (-1.72%)
     
  • DOW

    29,590.41
    -486.27 (-1.62%)
     
  • CRUDE OIL

    79.43
    -4.06 (-4.86%)
     
  • GOLD FUTURES

    1,651.70
    -29.40 (-1.75%)
     
  • NIKKEI 225

    27,153.83
    -159.30 (-0.58%)
     
  • HANG SENG

    17,933.27
    -214.68 (-1.18%)
     
  • DAX

    12,284.19
    -247.44 (-1.97%)
     
  • CAC 40

    5,783.41
    -135.09 (-2.28%)
     

Monoclonal Antibodies (MAbS) Global Market Report 2022: Increasing Product Launches and Regulatory Support for the Treatment of Rare Diseases to Fuel Future Growth

·4-min read
Company Logo
Company Logo

Global Monoclonal Antibodies (Mabs) Market

Global Monoclonal Antibodies (Mabs) Market
Global Monoclonal Antibodies (Mabs) Market

Dublin, Aug. 31, 2022 (GLOBE NEWSWIRE) -- The "Monoclonal Antibodies (MAbS) Global Market Report 2022: By Source, By Application, By End-User" report has been added to ResearchAndMarkets.com's offering.

The global monoclonal antibodies (MAbS) market is expected to grow from $168.70 billion in 2021 to $188.18 billion in 2022 at a compound annual growth rate (CAGR) of 11.5%. The market is expected to reach $292.22 billion in 2026 at a CAGR of 11.6%.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The increasing prevalence of cost-efficient biosimilar monoclonal antibodies are driving the monoclonal antibodies market growth. The biosimilar aim is to curb the increasing healthcare cost and handle economic pressure from the patient pod and governments to reduce the cost of medication and increase access to treatment. Biosimilar is the pharmaceuticals that are developed to have similar properties to a biologic drug that has already been approved. A biosimilar monoclonal antibody costs 20%-25% lesser than the originator biologic drug. The number of clinical trials for a biosimilar is comparatively lesser than that of the original biologic drug and this proves to be the reason for the low cost of a biosimilar drug. In India, a new biosimilar policy called the 'Guidelines on Similar Biologics' prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilar drugs industry.

Alternative treatment methods and natural remedies are increasingly becoming popular globally and this is expected to have a negative impact on the revenues of the monoclonal antibody drugs market. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, the revenue of US retail sales of homeopathic and herbal remedies was around $7.5 billion. These less expensive alternatives increase competitiveness for the biologics market putting downward pressure and limiting the demand for monoclonal antibody drugs.

The monoclonal antibodies market has been witnessing multiple strategic initiatives in recent years. Top companies in the market are strategically acquiring start-ups and mid-sized companies to broaden products and services. Strategic collaborations or acquisitions and partnership agreements help vendors expand their existing product portfolio and geographical reach. For instance, In February 2019, AbCellera and Novartis enter into a multi-target partnership to create an antibody-drug discovery platform and technology for treating clinically-relevant and neurodegenerative diseases.

Companies in the industry are increasingly realigning their portfolios and pursue profitable inorganic growth opportunities. Additionally, M&A interest is also being fueled by stronger corporate balance sheets, liquid debt markets, and continued favorable interest rates globally

The Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human Services, in the USA regulating the monoclonal antibodies and pharmaceutical drugs market. Increasing product launches and regulatory support for the treatment of rare diseases by USFDA is expected to support the monoclonal antibody therapeutics market growth.

Scope
Markets Covered:
1) By Source: Murine; Chimeric; Humanized; Human
2) By Application: Anti-Cancer; Immunological; Anti-Infective Monoclonal Antibodies (MAbs); Neuropharmacological; Cardiovascular And Cerebrovascular; Others
3) By End Users: Hospitals; Private Clinics; Research Institute

Key Topics Covered:

1. Executive Summary

2. Monoclonal Antibodies (MAbS) Market Characteristics

3. Monoclonal Antibodies (MAbS) Market Trends And Strategies

4. Impact Of COVID-19 On Monoclonal Antibodies (MAbS)

5. Monoclonal Antibodies (MAbS) Market Size And Growth

6. Monoclonal Antibodies (MAbS) Market Segmentation

7. Monoclonal Antibodies (MAbS) Market Regional And Country Analysis

8. Asia-Pacific Monoclonal Antibodies (MAbS) Market

9. China Monoclonal Antibodies (MAbS) Market

10. India Monoclonal Antibodies (MAbS) Market

11. Japan Monoclonal Antibodies (MAbS) Market

12. Australia Monoclonal Antibodies (MAbS) Market

13. Indonesia Monoclonal Antibodies (MAbS) Market

14. South Korea Monoclonal Antibodies (MAbS) Market

15. Western Europe Monoclonal Antibodies (MAbS) Market

16. UK Monoclonal Antibodies (MAbS) Market

17. Germany Monoclonal Antibodies (MAbS) Market

18. France Monoclonal Antibodies (MAbS) Market

19. Eastern Europe Monoclonal Antibodies (MAbS) Market

20. Russia Monoclonal Antibodies (MAbS) Market

21. North America Monoclonal Antibodies (MAbS) Market

22. USA Monoclonal Antibodies (MAbS) Market

23. South America Monoclonal Antibodies (MAbS) Market

24. Brazil Monoclonal Antibodies (MAbS) Market

25. Middle East Monoclonal Antibodies (MAbS) Market

26. Africa Monoclonal Antibodies (MAbS) Market

27. Monoclonal Antibodies (MAbS) Market Competitive Landscape And Company Profiles

28. Monoclonal Antibodies (MAbS) Pipeline Analysis

29. Key Mergers And Acquisitions In The Monoclonal Antibodies (MAbS) Market

30. Monoclonal Antibodies (MAbS) Market Future Outlook and Potential Analysis

31. Appendix

Companies Mentioned

  • Johnson & Johnson

  • Merck

  • AbbVie

  • Amgen

  • Glaxosmithkline plc.

  • Norvatis AG

  • Pfizer inc.

  • Thermofischer Scientific

  • Elililly and Company

  • Bristol-Myers Squibb

  • Hoffman Roche Ltd.

  • Sanofi

  • Abbott Laboratories

  • Mylan N.V

  • Novo Nordisk A/S

  • Daiichi Sankyo Company ltd.

  • Seattle genetics

  • Teva pharmaceutical industries

  • Shanghi Junsi bioscience ltd.

  • GenScript

  • Sigma-Aldrich Co. LLC

  • AbGenomics

  • ADC Therapeutics

  • Agensys

  • Alexion Pharmaceuticals

  • ALMAC Group

  • Ambrx

  • Astellas Pharma

  • Celgene

  • Celldex Therapeutics

For more information about this report visit https://www.researchandmarkets.com/r/6it9o9

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900